The Q1 beat was modest and margins compressed, but the real story is the China IDX divestiture, a strategic portfolio simplification that removes ~6% of revenue but could improve margins. The pro forma guidance implies H2 deceleration from Q1's 6% pro forma organic growth to ~3-4% for the full year. Watch for definitive agreement details in Q2 and whether proceeds are used for debt reduction or further buybacks. The stock may trade range-bound until the divestiture closes in 2027.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $92.30entry
- T+1 · 6mo ago +7.36%α +5.97% · $99.09
- T+5 · 6mo ago +7.58%α +5.60% · $99.30
- T+20 · 6mo ago +8.76%α +3.81% · $100.39
- T+60 · 4mo ago +23.01%α +20.27% · $113.54
Price Chart
How similar events traded
Executive Summary
Revvity reported Q1 2026 adjusted EPS of $1.06, beating the $1.02 consensus by 3.9%, on reported revenue of $711M (7% YoY growth, 3% organic). The company announced plans to divest its China Immunodiagnostics business (6% of 2025 revenue) for up to $200M and updated FY2026 pro forma guidance to $2.81-$2.84B revenue and $5.20-$5.30 adjusted EPS. While the quarter was solid, the divestiture introduces execution risk and the guidance implies a deceleration from Q1's pace, making the overall read-through mixed.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS from continuing operations: $0.37 (vs $0.35 YoY); adjusted EPS: $1.06 (vs $1.01 YoY)
- Q1 2026 reported revenue: $711M (7% YoY growth); organic revenue growth: 3%; pro forma organic growth: 6%
- Announced intention to divest China Immunodiagnostics business (~6% of FY2025 revenue) for up to $200M; LOI signed April 16, 2026; definitive agreement expected Q2 2026; close expected 2027
- Updated FY2026 pro forma guidance: revenue $2.81-$2.84B, pro forma organic growth 3%-4%, pro forma adjusted EPS $5.20-$5.30
- Prior FY2026 guidance (Feb 2026) was $2.96-$2.99B revenue and adjusted EPS $5.35-$5.45 on a reported basis; the new pro forma guidance excludes the China IDX business
- Life Sciences segment revenue: $362M (+6% YoY); Diagnostics: $349M (+8% YoY)
- Adjusted operating margin contracted to 23.6% from 25.6% YoY; GAAP operating margin was 10.7% vs 10.9%
- Operating cash flow from continuing operations: $125.9M vs $134.1M YoY; share repurchases of $86.5M in Q1
Financial Impact
Divestiture of China IDX for up to $200M; business represented ~$171M of FY2025 revenue (6% of total). Pro forma guidance implies FY2026 revenue of $2.81-$2.84B, down from prior $2.96-$2.99B reported guidance due to the exclusion.
Risk Factors
- Divestiture execution risk, definitive agreement not yet signed; regulatory approvals in China could delay or derail the deal
- Pro forma guidance implies slowing organic growth in H2 2026 vs Q1's 6% pro forma pace
- Adjusted operating margin declining YoY (23.6% vs 25.6%), cost pressures or mix shift
- Operating cash flow declined 6% YoY to $125.9M
- Restructuring charges of $10.7M in Q1 suggest ongoing cost-cutting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000031791-26-000016 |
| Document: q12026proformafinancialsta.htm | 0000031791-26-000016 |
| Document: pki-20260505.htm | 0000031791-26-000016 |
| Document: 0000031791-26-000016-index-headers.html | 0000031791-26-000016 |
| Document: 0000031791-26-000016-index.html | 0000031791-26-000016 |
| Document: 0000031791-26-000016.txt | 0000031791-26-000016 |
| 8-K Data (Synthetic) | 0000031791-26-000016 |
Track record
9 reports on RVTY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.31% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $150.78 Now $148.79 −1.32% settles Dec 15
- Nov 13, 20263d ago 8-K Neutral 4/10 Entry $156.51 Now $148.79 −4.94% settles Dec 14
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $163.48 Now $148.79 −8.99% settles Dec 2
- Oct 15, 20264w ago Institutional Cluster Neutral 3/10 Entry $154.64 to $158.25 Now $148.79 −3.79% ▲ +2.33% +3.75% vs SPY
- Oct 7, 20265w ago SC 13G/A Bullish 4/10 Entry $153.60 to $159.43 Now $148.79 −3.13% ▲ +3.80% +5.13% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 4/10 Entry $150.61 to $157.29 Now $148.79 +1.21% ▼ −4.43% −4.85% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 Entry $111.39 to $126.59 Now $148.79 +33.57% ▲ +13.65% +14.88% vs SPY
- May 5, 202627w ago 8-K Mixed 5/10 Viewing Entry $92.30 to $100.39 Now $148.79 +61.20% ▲ +8.76% +3.81% vs SPY
- Mar 16, 202635w ago DEFA14A Neutral 3/10 Entry $86.41 to $93.44 Now $148.79 +72.18% ▲ +8.13% +4.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers